Constellation Pharmaceuticals (NASDAQ:CNST) issued its quarterly earnings results on Thursday. The company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.03), Fidelity Earnings reports.
CNST traded up $0.11 on Friday, hitting $10.00. 18,491 shares of the company’s stock were exchanged, compared to its average volume of 61,866. Constellation Pharmaceuticals has a twelve month low of $4.01 and a twelve month high of $12.45.
Several analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. Robert W. Baird began coverage on shares of Constellation Pharmaceuticals in a research report on Monday, January 28th. They set an “outperform” rating and a $17.00 price target for the company. ValuEngine cut shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, HC Wainwright initiated coverage on shares of Constellation Pharmaceuticals in a research report on Thursday, December 20th. They set a “buy” rating and a $18.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $17.25.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
See Also: Index Funds
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.